<DOC>
	<DOCNO>NCT02168686</DOCNO>
	<brief_summary>The purpose study test safety primary efficacy gene transfer vector ( drug ) treatment alpha1-antitrypsin ( A1AT ) deficiency . The study use experimental drug ( ADVM-043 also know AAVrh.10halpha1AT ) deliver gene ( gene transfer ) treat sign symptom A1AT deficiency . Unlike drug , one make virus call adeno-associated virus ( AAV ) . In study , AAV act vehicle use carry A1AT gene lung cell treat cell .</brief_summary>
	<brief_title>Safety Study Gene Transfer Vector Treat Alpha1-antitrypsin ( A1AT ) Deficiency</brief_title>
	<detailed_description>This Phase 1/2 , randomize , open-label , parallel group , multicenter , dose-escalation study design evaluate safety preliminary efficacy ADVM-043 gene transfer vector follow intrapleural ( IP ) administration patient A1AT deficiency . As comparator IP route administration , equal number patient A1AT deficiency administer ADVM-043 vector intravenous ( IV ) infusion .</detailed_description>
	<mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protein C Inhibitor</mesh_term>
	<criteria>Capable providing informed consent ; A1AT genotype ZZ Z Null ; Males females 18 year old ; Patients receive A1AT protein augmentation therapy ( PAT ) least 2 month prior Screening visit individual receive A1AT PAT Screening , augmentation therapy stop 2 month allow augmentation therapy wash ; Serum A1AT level &lt; 11 µM ; Mild moderately severe emphysema quantitated HRCT ; Lung function parameter consistent presence emphysema individual FEV1 &gt; 1.2 L/sec ; Fertile men woman child bear potential agree use barrier birth control measure prevent pregnancy 1 month follow administration vector ; Willingness participate study . Individuals meet inclusion criterion ; Individuals receive systemic corticosteroid immunosuppressive medication ; Individuals immunodeficiency disease , evidence active infection type , include HIV ; Evidence major central nervous system , major psychiatric , musculoskeletal immune disorder ; Evidence chronic hepatitis B C infection ; History myocardial infarction cancer within past 5 year ( treat basal cell carcinoma skin ) ; Evidence infection define elevated white blood cell count , temperature &gt; 38.5°C infiltrate chest xray ; Creatinine &gt; 2 mg/dL ; Alanine transaminase &gt; 67.5 U/L ; Aspartate transferase &gt; 67.5 U/L ; Bilirubin ( total ) &gt; 1.9 mg/dL ; Bilirubin ( direct ) &gt; 0.6 mg/dL ; AAVrh.10 neutralize antibody titre &gt; 1:5 Screening ; Other significant laboratory abnormality may compromise patient 's safety participation study ; Pregnant lactating female ; Current alcohol drug abuse ; Any history allergy xylocaine , lidocaine , verse , valium , atropine , pilocarpine , isoproterenol , terbutaline , aminophylline , local anesthetic ; Individuals receive experimental medication participate another clinical trial least 3 month prior entry study ; Active smoker cigarette , tobacco use , ecigarettes recreational inhalant ( ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>alpha1-antitrypsin deficiency</keyword>
	<keyword>alpha1AT</keyword>
	<keyword>A1AT</keyword>
	<keyword>ADVM-043</keyword>
	<keyword>gene therapy</keyword>
	<keyword>gene transfer vector</keyword>
</DOC>